Short Interest in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Expands By 142.2%

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) was the target of a significant increase in short interest during the month of August. As of August 15th, there was short interest totaling 2,470,000 shares, anincreaseof142.2% from the July 31st total of 1,020,000 shares. Based on an average daily volume of 3,970,000 shares, the short-interest ratio is currently 0.6 days. Currently,17.3% of the shares of the stock are sold short. Currently,17.3% of the shares of the stock are sold short. Based on an average daily volume of 3,970,000 shares, the short-interest ratio is currently 0.6 days.

Analyst Upgrades and Downgrades

Several research firms recently commented on XFOR. HC Wainwright set a $3.50 target price on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 13th. Stifel Nicolaus cut their price target on shares of X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, August 29th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, X4 Pharmaceuticals has an average rating of “Buy” and an average target price of $34.17.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Kingdon Capital Management L.L.C. increased its stake in X4 Pharmaceuticals by 41.8% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after buying an additional 2,063,000 shares during the period. Pale Fire Capital SE increased its stake in X4 Pharmaceuticals by 45.2% in the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after buying an additional 633,398 shares during the period. Northern Trust Corp increased its stake in shares of X4 Pharmaceuticals by 2.9% during the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock worth $996,000 after purchasing an additional 37,940 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of X4 Pharmaceuticals by 4.0% during the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after purchasing an additional 24,948 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of X4 Pharmaceuticals by 134.9% during the 4th quarter. Jane Street Group LLC now owns 583,483 shares of the company’s stock worth $428,000 after purchasing an additional 335,036 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Stock Down 3.8%

X4 Pharmaceuticals stock opened at $3.50 on Friday. The firm has a market cap of $39.94 million, a PE ratio of -0.24 and a beta of 0.61. The company has a debt-to-equity ratio of 19.10, a quick ratio of 3.05 and a current ratio of 3.19. The firm’s 50 day moving average price is $2.33 and its two-hundred day moving average price is $4.79. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $26.83.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Friday, August 8th. The company reported ($3.47) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $1.06. The firm had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.62 million. X4 Pharmaceuticals had a negative net margin of 311.15% and a negative return on equity of 375.31%. On average, research analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.